De Kesel Pieter Mm, Sadones Nele, Capiau Sara, Lambert Willy E, Stove Christophe P
Laboratory of Toxicology, Ghent University, Faculty of Pharmaceutical Sciences, Harelbekestraat 72, 9000 Ghent, Belgium.
Bioanalysis. 2013 Aug;5(16):2023-41. doi: 10.4155/bio.13.156.
Dried blood spot (DBS) sampling for quantitative determination of drugs in blood has entered the bioanalytical arena at a fast pace during the last decade, primarily owing to progress in analytical instrumentation. Despite the many advantages associated with this new sampling strategy, several issues remain, of which the hematocrit issue is undoubtedly the most widely discussed challenge, since strongly deviating hematocrit values may significantly impact DBS-based quantitation. In this review, an overview is given of the different aspects of the 'hematocrit problem' in quantitative DBS analysis. The different strategies that try to cope with this problem are discussed, along with their potential and limitations. Implementation of some of these strategies in practice may help to overcome this important hurdle in DBS assays, further allowing DBS to become an established part of routine quantitative bioanalysis.
在过去十年中,用于血液中药物定量测定的干血斑(DBS)采样以快速的步伐进入了生物分析领域,这主要归功于分析仪器的进步。尽管这种新的采样策略有许多优点,但仍存在一些问题,其中血细胞比容问题无疑是讨论最为广泛的挑战,因为严重偏离的血细胞比容值可能会显著影响基于DBS的定量分析。在本综述中,对定量DBS分析中“血细胞比容问题”的不同方面进行了概述。讨论了试图应对这一问题的不同策略及其潜力和局限性。在实践中实施其中一些策略可能有助于克服DBS分析中的这一重要障碍,进而使DBS成为常规定量生物分析的既定组成部分。